Nature's Shot at Cancer
An unlisted Australian biotech (pre-IPO) turning rainforest-derived small molecules into new medicines through its platform technology. With its lead injectable anticancer drug showing promise across a range of solid tumours and receiving standout early trial results, its sights are set on a pharma partnership and future IPO.
Bull Case
Standout data in hard-to-treat cancer
Four in five injected tumours shrank or vanished; most not returning at six months.
Lead drug delivered directly into the tumour, not through the bloodstream
Destroys the tumour at the source with minimal side effects while also triggering a systemic immunological response. This solution has a large market potential.
Not just a single drug but a platform of interrelated programmes
Family of unique small molecules underpins multiple programmes, with breadth and continuity that a single-asset company lacks.
A focused strategy aimed at an IPO
With commercial manufacturing capability in place and proof-of-concept data demonstrated, ambitions set on a commercial partner and float.
Bear Case
Multiple small trials point to broad potential, but a long road ahead
Early-stage trials with no Phase III yet mean bigger studies could disappoint.
A stretched balance sheet
Cash reserves have reduced, and more funding will be needed to continue.
Despite being a broad platform technology, a lot rides on the lead programme
Value rests on the anticancer programme and on securing a pharma partner.
CurationAI can make mistakes, this is not investment advice. QBiotics Group is a client of Curation.